StemCell Therapy

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in the SVB Securities Global Biopharma Conference and Cowen’s 43rd Annual Health Care Conference. Details of participation are as follows:

View post:
Tenaya Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today:

Read more here:
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares

ASKA Pharmaceutical : February 7 2023 EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical VHH to address an unmet medical need in Obstetrics and Gynecology  Marketscreener.com

See original here:
ASKA Pharmaceutical : February 7 2023 EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical VHH to address an unmet medical...